821 / 1835
Response Rates
IRRC
(N = 80)
Investigator
(N = 80)
Objective response rate, n (%)
95% CI
53 (66)
55–76
58 (73)
61–82
Best overall response, n (%)
Complete remission
Partial remission
Stable disease
Progressive disease
Unable to determine
7 (9)
46 (58)
18 (23)
6 (8)
3 (4)
22 (28)
36 (45)
18 (23)
3 (4)
1 (1)
CheckMate 205B
Patients with no prior response to most
recent brentuximab vedotin treatment
IRRC
(N = 43)
Investigator
(N = 43)
Objective response rate, n (%)
31 (72)
35 (81)